EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

F Shawket, J Lycke, J Salzer, F Piehl iD, K Fink, N Lange, J Mellergård, C Malmeström, P Sundström, I Erngren, A Al-Grety, E Freyhult und 3 weitere

Annals of Clinical and Translational Neurology · 2026-11 · 13 (11) · 2278-2288

DOI: 10.1002/acn3.70395 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 12.04.2026. Verfasst von F Shawket und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital and Department of Neurology, Danderyd Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Dimethyl Fumarate, Multiple Sclerosis, Relapsing-Remitting, Rituximab, Neurofilament Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Region Uppsala, Vetenskapsrådet, Västerbotten Läns Landsting.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.

Methods

RIFUND‐MS was a 2‐year, rater‐blinded, 1:1 randomized controlled multicenter trial comparing DMF and RTX in relapsing–remitting multiple sclerosis (RRMS). Serum samples for analysis of sNFL and sGFAP were collected at baseline and 0, 6, 12 and 24. Log‐transformed biomarker data were analyzed with linear mixed models, based on intention to treat (ITT), per protocol (PP) and accounting for therapy switches. Cox proportional hazards models were performed to evaluate progression outcomes.

Results

Of 200 participants, 197 were analyzed. Based on ITT, sNfL decreased significantly in both arms from baseline to month 24; by 50.7% (CI 43.7%–56.8%; p < 0.001) with RTX, and by 46.4% (CI 38.6%–53.2%; p < 0.001) with DMF, no differences between treatments (global p ‐value: ITT = 0.06; PP = 0.08; switch group = 0.15). In contrast, sGFAP remained stable in RTX (3.6% decrease; CI −7.8%–13.8%, p = 0.81) but decreased with DMF (18.4%; CI 8.5%–27.2%; p < 0.001). Global analyses favored DMF (ITT = 0.02; PP = 0.004; switch group = 0.74). The risk of progression independent of relapse and MRI activity (PIRMA) was higher with RTX (HR 3.3, CI 1.1–10, p = 0.04).

Interpretation

Both RTX and DMF reduced sNfL levels, consistent with suppression of acute inflammatory disease activity. However, only DMF was associated with a sustained reduction in sGFAP and a lower risk of non‐inflammatory disability progression. These findings suggest that DMF may exert additional effects on astrocyte‐related or compartmentalized CNS pathology beyond peripheral immune modulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dimethyl FumarateMultiple Sclerosis, Relapsing-RemittingRituximabNeurofilament ProteinsGlial Fibrillary Acidic ProteinImmunosuppressive AgentsImmunologic FactorsHumansFemaleAdultMaleMiddle AgedBiomarkersDisease Progression

Stichwörter der Autor:innen

PIRMAbiomarkersdimethyl fumaratemultiple sclerosis

Substanzen

Dimethyl FumarateRituximabNeurofilament ProteinsGlial Fibrillary Acidic Proteinneurofilament protein LImmunosuppressive AgentsGFAP protein, humanBiomarkersImmunologic Factors

Autor:innen und Institutionen

  • Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital and Department of Neurology, Danderyd Hospital, Stockholm, Sweden.
  • Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
  • Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.
  • Department of Clinical Neuroscience, Karolinska Institutet, Department of Neurology, Karolinska University Hospital, and Academic Specialist Center, Stockholm, Sweden.
  • Department of Neurology, Örebro University, Örebro, Sweden.

ORCID-Profile: F Piehl, A Svenningsson

Förderung

  • Region Uppsala
  • Vetenskapsrådet
  • Västerbotten Läns Landsting
  • Region Östergötland
  • Region Örebro län
  • Västra Götalandsregionen
  • Hjärnfonden

Zitieren

APA

Shawket, F., Lycke, J., Salzer, J., Piehl, F., Fink, K., Lange, N., Mellergård, J., Malmeström, C., Sundström, P., Erngren, I., Al-Grety, A., Freyhult, E., Kultima, K., Burman, J., & Svenningsson, A. (2026). Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS. Annals of Clinical and Translational Neurology, 13(11), 2278-2288. https://doi.org/10.1002/acn3.70395

Vancouver

Shawket F, Lycke J, Salzer J, Piehl F, Fink K, Lange N, et al. Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS. Annals of Clinical and Translational Neurology. 2026;13(11):2278-2288. doi:10.1002/acn3.70395

BibTeX
@article{Shawket2026,
  author = {Shawket, F and Lycke, J and Salzer, J and Piehl, F and Fink, K and Lange, N and Mellergård, J and Malmeström, C and Sundström, P and Erngren, I and Al-Grety, A and Freyhult, E and Kultima, K and Burman, J and Svenningsson, A},
  title = {Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  volume = {13},
  number = {11},
  pages = {2278--2288},
  doi = {10.1002/acn3.70395}
}
Kostenlos starten →